Publications

The NSH-BMT and Leukemia Programs are committed to publishing in the field of blood and marrow transplantation, Leukemia and hematologic malignancies. The following publications/presentations demonstrate this commitment.

Society Oral Presentations/Posters:

ASH 2018

Oral Presentations:

Solomon S, Aubrey M, Anobile C, Zhang X, Freed B, Morris LE, Holland HK, Solh M, Bashey A.  Class II epitope level mismatch can predict chronic graft-versus-host disease and survival following haploidentical transplant using post-transplant cyclophosphamide. ORAL ABSTRACT #311                       

Solomon S, Martin A, Shah N, Fatobene G, Al Malki, M, Ballen K, Bashey A, Bejanyan N, Bolanos-Meade J, Brunstein C, Defilipp Z, Champlin R, Fuchs E, Hamadani M, Hematti P, Kanakry C, McGuirk J, McNiece I, Ciurea S, Pasquini M, Rocha V, Romee R, Patel S, Vasu S, Waller E, Wingard J, Zhang M, Eapen M.  T-replete haploidentical cell transplantation using post-transplant cyclophosphamide for acute myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome:  Effect of transplant conditioning regimen intensity of outcomes.  ORAL ABSTRACT #1015

Solh M, Solomon S, Morris LE, Holland HK, Zhang X, Bashey A.  The choice of induction regimen affects post remission survival of acute myelogenous leukemia (AML) patients with intermediate or poor risk disease.  ORAL ABSTRACT #82

Collaborative Oral Presentation:

Caimi P, Kahl B, Hamadani M, Carlo-Stella C, Ardeshna KM, Radford J, Solh M, Heffner L, He, S, Ungar D, Qin Y, O’Connor OA.  Safety and efficacy of ADCT-402 (loncastuximab tesirine) a novel antibody drug conjugate in relapsed/refractory follicular lymphoma and mantle cell lymphoma: Interim results from the phase I first in human study. ORAL ABSTRACT #626                         

Poster Presentations:

Solomon S, Jackson K, Zhang X, Solh, M, Bashey A, Holland HK, Morris LE.  Treatment patterns and outcomes of unselected elderly acute myeloid leukemia (AML) patients referred to a combined acute leukemia and hematopoietic stem cell transplant (HSCT) program. POSTER ABSTRACT #2675

Solomon S, Zhang X, Solh M, Morris LE, Holland HK, Bashey A.  Long-term follow-up of myeloablative haploidentical (HID) peripheral blood stem cell transplantation and post-transplant cyclophosphamide (PTCy) following fludarabine and total body irradiation (TBI). POSTER ABSTRACT # 3368

Ravandi-Kashani F, Abboud C, Akard L, Gill S, Hsu J, Kambhampati S, Khan I, Delong L, Stock W, Brown J, Bashey A, Borthakur G, Dinardo C, Holland HK, Kadia T, Kantarjian H, Morris LE, Solomon S, Mamelok R, Panuganti S, Syoc R, Wong A, Zimmerman D, Solh M. Evaluation of ASH 2018 romyelocel-L myeloid progenitors cells to decrease infections in de novo AML patients receiving high-dose ara c-based induction therapy. POSTER ABSTRACT #1407 

ASBMT Tandem Meeting 2018

Oral Presentation:
Solh M, Zhang X, Brown S, Morris LE, Holland HK, Bashey A, Solomon S. The dilemma of conditioning intensity:  When does myeloablative conditioning improve outcomes for allogeneic hematopoietic cell transplantation?  ORAL ABSTRACT # 68

Post Presentations:
Sizemore C, Ridgeway M, Zhang X, Morris LE, Holland HK, Solh M, Bashey A, Solomon S.  Rituximab based on first line treatment for chronic GVHD following allogeneic transplant:  Single center analysis of 95 patients.  POSTER ABSTRACT # 224 

Kronemberg O, Miller J, Sizemore C, Hanik M, Brown S, Bashey A, Solomon S, Morris LE, Holland HK, Solh M.  A prospective pilot study of implementing a sepsis management protocol among adult hematopoietic stem cell transplant recipients.  POST ABSTRACT # 564.

ASH 2017

Oral Presentation:
Solomon S, Aubrey M, Zhang X, Piluso A, Freed B, Brown S, Jackson K, Solh M, Morris LE, Holland HK, Bashey A.  Selecting the best donor for T cell-replete haploidentical transplantation:  Importance of HLA disparity, NK alloreactivity, and other clinical variables.  ORAL ABSTRACT #670 

Collaborative Oral Presentation:

Kahl B, Hamadani M, Caimi P, Carlo-Stella C, Reid E, Feingold J, Ardeshna K, Radford J, Solh M, Hung K-Y, Heffner L, He S, Boni J, O’connor O.  Early results from the first in human clinical trial of ADCT-402 (Loncastuximab Tesirine), a novel pyrrolobenzodiazepine based antibody drug conjugate, in relapsed/refractory B-cell lineage non-hodgkin lymphoma ORAL ABSTRACT #670 

Poster Presentations:
Bashey A, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, Solh M, Solomon S.  Comparison of outcomes following allogeneic HCT for adverse cytogenetic/molecular risk AMl using T-replete haploidentical donors to optimally matched related and unrelated donors. POSTER ABSTRACT #4608

Solh M, Bashey A, Zhang X, Morris LE, Holland KH, Solomon S.  Myeloablative hematopoietic cell transplantation (HCT) for low and intermediate disease risk index myeloid malignancies results in better outcomes compared to reduced intensity HCT. POSTER ABSTRACT #2050

Baron J, Ridgeway M, Zhang X, Bashey A, Solomon S, Holland HK, Morris LE, Solh M.  Identifying risk factors for acute and chronic graft versus host disease in T-replete HLA-haploidentical hematopoietic cell transplantation with post transplant cyclophosphamide. POSTER ABSTRACT #1977

Solh M, Zhang X, Solomon S, Morris LE, Holland HK, Bashey A.  Who is a better donor for recipients of allogeneic hematopoietic cell transplantation:  A young HLA haploidentical relative or an older fully matched HLA-matched sibling or unrelated volunteer? POSTER  ABSTRACT #4604 

Collaborative Poster Presentation:
 
Goldberg, A, Tallman M, Solh M, Ungar D, Rizzieri D, Walter R, Spira A, Chung K-Y, Stock W, He S, Boni J, Atallah E.  Interim data from a phase 1 study evaluating pyrrolobenzodiazapine-based antibody drug conjugate ADCT-301 (Camidanlumab Tesirine) for relapsed or refractory CD25-positive acute leukemia. POSTER ABSTRACT #302

ASBMT Tandem Meeting 2017

Oral Presentations:

Sanacore M, Eaton S, Morris LE, Solomon S, Bashey A, Solh M, Holland HK.  Prospective assessment of diagnostic infectious disease molecular PCR testing with early fiber-optic bronchoscopy (FOB) in the evaluation of new pulmonary infiltrates in hematopoietic stem cell transplantation (HSCT) and acute leukemia (AL) patients (pts). ORAL ABSTRACT # 9355

Solh M, Dickhaus E, Gruber L, Bashey A, Solomon S, Holland HK, Morris LE, Brown S.  Fevers post infusion of T-cell replete HLA mismatched haploidentical hematopoietic stem cells.  ORAL ABSTRACT
 # 8901

Poster Presentations:

Solh M, Gorgeis J, Sizemore C, Solomon S, Holland HK, Morris LE, Bashey A.  Nitazoxanide is effective therapy for norovirus gastroenteritis after hematopoietic stem cell transplantation.  POSTER ABSTRACT # 348

Solomon S, Aubrey, Zhang X, Freed B, Piluso A, Connor K, Brown S, Holland HK, Morris LE, Solh M, Bashey A.  Impact of donor characteristics on transplant outcome following haploidentical hematopoietic cell transplantation utilizing post-transplant cyclophosphamide:  Improving donor selection criteria.  POSTER ABSTRACT # 309

LaPorte J, Leon K, Zhang X, Morris LE, Solomon S, Holland HK, Solh M, Bashey A.  A unique schedule of Palanosetron, Ondansetron and Dexamethasone for the prevention of delayed nausea and vomiting in patients receiving myeloablative chemotherapy. POSTER ABSTRACT # 230

ASH 2016

Oral Presentations:

Current graft-versus-host-disease (GVHD), relapse-free Survival – a novel, dynamic composite endpoint to better define effectiveness following allogeneic hematopoietic cell transplantation. Solomon S, Sizemore C, Ridgeway M, Zhang X, Solh M, Morris LE, Holland HK, Bashey A. ORAL ABSTRACT # 1170

Myeloablative allogeneic hematopoietic cell transplantation performed without routine inpatient admission: A single center experience of 462 consecutive patients. Bashey A, Zhang X, Brown S, Jackson K, Solh M, Lawrence M, Holland HK, Solomon S. ORAL ABSTRACT # 661

Comparison of peripheral blood stem cells (PBSC) to bone marrow (BM) for T-replete HLA-Haploidentical donor transplantation using post-transplant cyclophosphamide. Bashey A, Zhang M, Mccurdy S, Ciurea S, St. Martin A, Anasetti C, Argall T, Fasan O, Gaballa S, Hamandani M, Malki M, Munshi P, Nakamura R, O’donnell P, Perales M, Raj K, Rocha V, Romee R, Rowley S, Salit R, Solh M, Soiffer R, Wingard J, Weisdorf D, Horowitz M, Fuchs E, Eapen M. ORAL ABSTRACT # 683

Poster Presentations:

Excellent long term survival among patients who are disease-free at one year after allogeneic hematopoietic cell transplantation:  A single center analysis of 667 consecutive patients.  Solh M, Bashey A, Solomon S, Morris LE, Zhang X, Brown S, Holland HK. POSTER ABSTRACT # 4622

Outcomes for allogeneic hematopoietic cell transplantation for AML and high grade MDS in older adults in the era of T-replete haploidentical donor grafts.  A single center multivariate analysis. Solh M, Bashey Z, Solomon S, Morris LE, Holland HK, Zhang X.  POSTER ABSTRACT # 4665

Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation (HCT):  A single center analysis of 613 adult HCT recipients using a modified composite endpoint. Solh M, Morris LE, Holland HK, Solomon S, Brown S, Bashey A.  POSTER ABSTRACT # 4574

ASH 2015

Oral Presentation:

Non-Inferior survival of black versus white patients and superior outcomes for black females compared to other race/gender groups following allogeneic transplantation for hematologic malignancy: A single center multivariable analysis of 475 allografted patients. Bashey A, Zhang X, Jackson K, Brown S, Solh M, Morris LE, Holland HK, Solomon S. 57th Annual ASH Meeting. Oral Abstract #401

Poster Presentations:

Lineage specific chimerism analysis reveals that mixed donor T-cell chimerism is common in the early post-transplant period following myeloablative allotransplants from HLA-matched but not HLA-haploidentical donors: A multivariable analysis of allografted patients from a single center. Bashey A, Zhang X, Jackson K, Brown S, Solh M, Morris LE, Holland HK, Solomon S. 57th Annual ASH Meeting. POSTER ABSTRACT #4327

Solomon S, Sizemore C, Zhang X, Solh M, Morris LE, Holland HK, Bashey A. Disease risk index is the major predictor of outcome following myeloablative haploidentical hematopoietic stem cell transplantation (haplo-HSCT) and post-transplant cyclophosphamide (PT/Cy). 57th Annual ASH Meeting. POSTER ABSTRACT #2010

Solomon S, Sizemore C, Zhang X, Connor K, Solh M, Holland HK, Morris LE, Bashey A. Disease risk and host factors, not transplant type, predict outcome following allogeneic hematopoietic stem cell transplantation for acute leukemia. 57th Annual ASH Meeting. POSTER ABSTRACT #4372

Solomon S, Sanacore M, Zhang X, Connor K, Solh M, Bashey A, Morris LE, Holland HK. Targeted oral busulfan (BU/cyclophosphamide (CY)/VP-16 and autologous stem cell transplant (ASCT) for Hodgkins’s (HL) and non-hodgkin’s lymphoma (NHL) results in excellent 5-year survival and low treatment related mortality: Ten-year single center experience of 246 consecutively treated patients. 57th Annual ASH Meeting. POSTER ABSTRACT #3185

Solomon S, Sanacore M, Zhang X, Connor K, Solh M, Morris LE, Holland HK, Bashey A. In vivo T cell depletion with thymogobulin of alemtuzumab is associated with worse outcome following allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients transplanted in remission. 57th Annual ASH Meeting. POSTER ABSTRACT #3115

Solh M, Zhang X, Brown S, Morris LE, Holland HK, Solomon S, Bashey A. Lower use of DLI post relapse of malignancy may result in shorter post-relapse survival (PRS) in patients undergoing T cell replete haploidentical donor transplantation (HIDT) versus matched related (MRD) or matched unrelated donor (MUD) hematopoietic cell transplantation (HCT). 57th Annual ASH Meeting. POSTER ABSTRACT #1967

Solh M, Connor K, Zhang X, Brown S, Morris LE, Holland HK, Bashey A. Solomon S. T cell replete HLA- haploidentical donor transplantation (HIDT) with post-transplant cylophosphamide (pTcy) is an effective salvage for patients relapsing after a matched sibling or a matched unrelated donor transplantation. 57th Annual ASH Meeting. POSTER ABSTRACT #1960

Solh M, Zhang X, Connor K, Brown S, Holland HK, Morris LE, Solomon S, Bashey A. Factors predicting GVHD free, relapse free survival (GRFS) after allogeneic hematopoietic cell transplantation; a multivariable analysis of 531 allografts from a single center. 57th Annual ASH Meeting. POSTER ABSTRACT # 2028

Collaborative ASH Abstracts

Bart L Scott, MD, Marcelo C. Pasquini, MD, Brent Logan, PhD, Juan Wu, Steve Devine, MD*, David L Porter, MD, Richard T. Maziarz, MD, Erica Warlick, MD, Hugo F. Fernandez, M.D., Edwin P. Alyea, MD, Mehdi Hamadani, MD, Asad Bashey, MD, PhD, Sergio A. Giralt, MD, Eric Leifer, PhD, Nancy Geller, PhD, Jennifer Le-Rademacher, PhD, Adam M. Mendizabal, PhD, Mary M. Horowitz, MD, MS, H. Joachim Deeg, MD1 and Mitchell E. Horwitz, MD, Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN), 57th Annual ASH Meeting. ABSTRACT #0901

Matthew S. Davids, MD, Haesook T. Kim, PhD, Caitlin L. Costello, MD, Peter A. McSweeney, MD, Rebecca Liguori, Alexander Lukez, David Avigan, MD, Yi-Bin Chen, MD, Nicole LeBoeuf*, Vincent T. Ho, MD, Corey S Cutler, MD, MPH, John Koreth, MBBS, DPhil, Edwin P. Alyea, MD5, Joseph H Antin, MD5, Jerome Ritz, MD, Philippe Armand, MD, PhD, Edward D Ball, MD, Asad Bashey, MD, PhD and Robert J. Soiffer, MD, A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation, 57th Annual ASH Meeting, ABSTRACT #860

Anand Jillella, MD1, Martha Arellano, MD, Asad Bashey, MD, PhD, Sarah I. Vidito, DO, Robert K. Stuart, MD, Caleb Leung*, Kaitlin Sitchenko, Manila Gaddh, MD, Leonard T Heffner Jr., MD, Ravindra B. Kolhe, MD, PhD*, Jacques Galipeau, MD, Amelia Langston, MD and Vamsi K Kota, MD, Decreasing Early Deaths in Acute Promyelocytic Leukemia (APL) By Using a Simplified Treatment Algorithm and Establishing a Network with Academic and Community Centers in USA, 57th Annual ASH Meeting, ABSTRACT #3779

Randomized Phase II Trial of Timed Sequential Cytosine Arabinoside with and without the CHK1 Inhibitor MK-8876 in Adults with Relapsed and Refractory Acute Myelogenous Leukemia, Jonathan Allen Webster, MD, Raoul Tibes, MD, PhD, Amanda Blackford, ScM, Lawrence Morris, MD, Mrinal M Patnaik, MBBS, Lihua Wang, PhD, Melanie Rebechi, BS, Jacqueline Greer, RN, Mark R Litzow, MD, Larry Karnitz, PhD, Gary L. Rosner, Austin Doyle, MD, Scott H. Kaufmann, MD, PhD, Judith E Karp, MD and B. Douglas Smith, MD, 57th Annual ASH Meeting, ABSTRACT # 2563

ASH 2014

Oral Presentations:

TBI-Based Myeloablative Haploidentical Stem Cell Transplantation is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients without Matched Sibling Donors – Scott R. Solomon, M.D., H. Kent Holland, M.D., Lawrence E. Morris, M.D., Asad Bashey, M.D., Ph.D., Connie Sizemore, PharmD, Xu Zhang, Ph.D., Stacey Brown, B.A., Katelin Connor, B.S. ORAL ABSTRACT #426

The Psychosocial Transplant Evaluation Rating Scale (TERS) Prospectively Predicts Inferior Overall Survival Outcome for High Risk Scoring Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Dawn Speckhart, Ph.D, H. Kent Holland, M.D., Scott R. Solomon, M.D., Lawrence E. Morris, M.D. Asad Bashey, M.D., Ph.D, Xu Zhang, Ph.D. POSTER ABSTRACT #207

Survival after T-Replete Haplo-identical Related Donor Transplants Using Post-Transplant Cyclophosphamide Compared with Match Unrelated Donor Transplantation for Acute Myeloid Leukemia: An Analysis from the CIBMTR. Stefan O. Ciurea, M.D., Mei-Jie Zhang, M.D., Andrea Bacigalupo, M.D., Asad Bashey, M.D., Ph.D., et.al. ORAL ABSTRACT # 679

Poster Presentations:

Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in Excellent Responses and Rapid Time to Immunosuppression Discontinuation. Connie Sizemore, PharmD, Scott R. Solomon, M.D., Lawrence E. Morris, M.D., H. Kent Holland, M.D., Asad Bashey, M.D., Ph.D. Michelle Ridgeway, RN, OCN, Xu Zhang, Ph.D., Stacey Brown, B.A. POSTER ABSTRACT #2487

Flag-Idarubicin Is Superior to Cytarabine Plus Idarubicin (7+3) for Initial Treatment of Acute Myeloid Leukemia (AML): A Multivariable Analysis of Patients Treated at a Single Center. Ron Mihelic, PharmD, BCOP, H. Kent Holland, M.D., Scott R. Solomon, M.D., Lawrence E. Morris, M.D., Asad Bashey, M.D., Ph. D., Xu Zhang, Ph.D., Elizabeth Dickhaus, PharmD, Stacey Brown, B.A. POSTER ABSTRACT # 3728

Use of the Dana-Farber/CIBMTR Disease Risk Index (DRI) to Compare Outcomes of T-Replete HLA-Haploidentical Transplants Using Post-Transplant Cyclophosphamide to Matched Sibling and Matched Unrelated Donor Transplants: A Multivariate Analysis of 498 contemporaneous Allogeneic Transplants from a Single Center. Asad Bashey, M.D., Ph.D., H. Kent Holland, M.D., Lawrence E. Morris, Scott R. Solomon, M.D., Xu Zhang, Ph.D, Stacey Brown, B.A., Katelin Connor, B.S. POSTER ABSTRACT #1203

Chronic GVHD Is Not Increased with the Use of PBSC Instead of Bone Marrow for T-Replete HLA-Haploidentical Transplantation Using Post-Transplant Cyclophosphamide: A Multivariate Analysis of 116 Consecutive Transplants from a Single Center. Asad Bashey, M.D., Ph.D., H. Kent Holland, M.D., Lawrence E. Morris, M.D., Scott R. Solomon, M.D., Xu Zhang, Ph.D., Stacey Brown, B.A., Katelin Connor, B.S. POSTER ABSTRACT #3922

Impact of Age on Outcomes Following Autologous Stem Cell Transplantation for Multiple Myeloma. Justin LaPorte, PharmD, H. Kent Holland, M.D., Lawrence E. Morris, M.D., Scott Solomon, M.D., Asad Bashey, M.D., Ph.D., Xu Zang, Ph.D., Stacey Brown, B.A. POSTER ABSTRACT #3968

ASBMT Tandem Meeting: 2014
Poster Presentation:

Outcomes of Relapse of AML Post Allogeneic Transplantation in the Era of Hypomethylating Agents: An Analysis of 162 Allogeneic Transplants from a Single Center. Laporte,J, Mihelic R , Sanacore M, Sizemore C, Leech M, Holland HK, Morris LE, Solomon S, Bashey A.

FLAG-Idarubicin is Superior to Cytarabine plus Idarubicin (7+3) for Initial Treatment of Acute Myeloid Leukemia (AML): A Multivariable Analysis of Patients Treated At A Single Center. Mihelic, R, Sanacore M, Sizemore C, Leech M, Laporte, Holland HK, Morris LE, Solomon S, Bashey A.

ASH 2013

Oral Presentation:

Calcineurin Inhibitor-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide and Brief-Course Sirolimus Results in Low Rates of Non-Relapse Mortality and Chronic GVHD Following Matched Related and Unrelated Donor Peripheral Blood Stem Cell Transplantation (PBSCT). Melissa Sanacore, PharmD1*, Asad Bashey, MD, PhD1, Connie A. Sizemore, PharmD1*, H. Kent Holland, MD1, Lawrence E. Morris, MD1, Stacey Brown, B.A.1*, Xu Zhang, PhD2* and Scott R. Solomon, MD 1

Poster Presentations:

Overall and Disease-Specific Outcomes Following T-Cell Replete Haploidentical Transplants Using Post-Transplant Cyclophosphamide: An Analysis Of 115 Patients Transplanted At a Single Center -- Asad Bashey, MD, PhD, Xu Zhang, PhD, Zaamin Hussain, Stacey Brown, B.A., Lawrence E. Morris, MD, H. Kent Holland, MD, Scott R. Solomon, MD.

Myeloablative Conditioning With PBSC Grafts For T-Replete Haploidentical Donor Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide Results In Universal Engraftment, Low Rates Of Gvhd, NRM and Excellent Survival Outcomes: An Analysis Of Two Consecutive Phase II Studies From a Single Center -- Scott R. Solomon, MD, Stephanie Jacobson, FNP-C, OCN, Melissa Sanacore, PharmD, Xu Zhang, PhD, Connie Sizemore, Pharm.D., Stacy Brown, B.A., H. Kent Holland, MD, Lawrence E. Morris, MD, Asad Bashey, MD, PhD.

Validation of a brief arsenic trioxide (ATO)-based consolidation chemotherapy in the upfront management of acute promyelocytic leukemia (APL): less anthracycline exposure and faster completion of consolidation therapy with equivalent survival. Mindy Leech, Moshe Stewart, Xu Zhang, Asad Bashey, Kent Holland, Scott Solomon, Hetty Caraway, B Douglas Smith, Lawrence Morris, Steven D. Gore, and Amer M. Zeidan.

Implementation of a Systematic Approach to Increase Occurrence and Documentation of Fertility Discussions in Newly Diagnosed Acute Leukemia Patients Prior to Induction Chemotherapy. Dawn Speckhart, PhD, Scott R. Solomon, MD, Asad Bashey , MD , Lawrence E. Morris Jr, MD, H. Kent Holland, MD.

Outcomes of Relapse of AML Post Allogeneic Transplantation in the Era of Hypomethylating Agents: An analysis of 162 Allogeneic Transplants from a Single Center Justin LaPorte, Xu Zhang, Zaamin Hussain, Stacey L. Brown, Connie Sizemore, Melissa Sanacore, Ron Mihelic, Mindy Leech, Lawrence E. Morris Jr,MD, H. Kent Holland, MD, Scott R. Solomon, MD, and Asad Bashey, MD.

ASBMT Tandem Meeting: 2013
Poster Presentation:

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome.  Sizemore C, Zang X, Sanacore M, Bashey A, Solomon S, Morris LE, Holland HK.

2013 11th Annual American Psychosocial Oncology Association Meeting

Oral Presentation:

Disease Comorbidity Predicts Length of Hospitalization Whereas Psychosocial Risk Predicts Patient Survival One Year Post Hematopoietic Stem Cell Transplantation’, Abstract # 0250. Dawn Speckhart, Ph.D., University of Colorado, Denver and the Colorado Blood Cancer Institute, Presbyterian/St.Luke’s Medical Center.

Implementation of a Systematic Approach to Increase Occurrence and Documentation of Fertility Discussions in Newly Diagnosed Acute Leukemia Patients Prior to Induction Chemotherapy’. Dawn Speckhart, Ph.D.

ASH 2012

Poster Presentation(s):

Maintenance Hypomethylating Therapy Post Allogeneic Stem Cell Transplantation Provides Favorable Progression Free Survival in High Risk Acute Myelogenous Leukemia or Non Responsive Myelodysplastic Syndrome.   Poster at NCI’s International Workshop on the Biology, Prevention and Treatment of Relapse after Hematopoietic Stem Cell Transplantation .  Sizemore C, Zang X, Sanacore M, Bashey A, Solomon S, Morris LE, Holland HK.

Lineage-Specific Chimerism and Incidence of Graft Failure Following T-Cell Replete Haploidentical Transplantation Using Post-Transplant Cyclophosphamide in Eight-Nine Consecutive Patients From a Single Center Hussain A, Sizemore C, Zhang X, Sanacore M, Brown S, Manion K, Morris LE, Holland HK, Solomon S, Bashey A.

Assessing Fatigue and Distress in Caregivers of Hematopoetic Stem Cell Transplant PatientsSpeckhart D, Solomon S, Holland HK, Morris LE, Bashey AB.

ASBMT Tandem Meeting - 2012
Oral Presentation:

Effect of Cytoxan dosing on hematopoietic stem cell (HSC) mobilization efficacy, toxicity and cost in successive cohorts of non-hodgkin’s lymphoma (NHL) patients. Sanacore M, Sizemore C, Zhang X, Schipani B, Morris LE, Bashey A, Holland HK, Solomon S.    

Poster Presentations:

Pharmacy driven posaconazole therapeutic monitoring in leukemia and bone marrow transplant center Leech M, Laporte J, Mihelic R, Sanacore M, Sizemore C, Holland HK, Morris LE, Solomon S, Bashey A.

Voriconazole therapeutic monitoring in a leukemia and bone marrow transplant center.  Leech M, Laporte J, Mihelic R, Sanacore M, Sizemore C, Holland HK, Morris LE, Bashey A, Solomon S.

An effective hematopoietic stem cell mobilization algorithm for adding plerixafor to G-CSF for multiple myeloma patients undergoing autologous transplantation.  Laporte J.  Leech M, Mihelic R, Sanacore M, Sizemore C, Zhang X, Holland HK,  Morris LE, Bashey A, Solomon S.

-----Back To Top-----

ASH 2011

Oral Presentations:

Haploidentical transplantation using T-cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival:  Results of a prospective phase II trial. Sizemore C, Bashey A, Sanacore M, Manion K, Holland HK, Morris LE, Brown S,Zhang X, Solomon S.

T-Cell replete haploidentical transplantation using post-transplant cyclophosphamide results in equivalent non-relapse mortality and disease-free survival compared to transplantation from HLA-identical sibling and matched unrelated donors:  A stratified cox model analysis of two hundred and sixty   contemporaneous allogeneic transplants from a single center.  Bashey A, Zhang X, Sizemore C, Manion K, Brown S, Holland HK, Solomon S, Morris LE.

Low dose subcutaneous alemtuzumab and preemptive donor lymphocyte infusion without withdrawal of immunosuppression results in low non-relapse mortality, decreased hospitalization, and favorable outcomes for high risk older recipients of unrelated donor allogeneic transplants:  A prospective
phase II trial. Sizemore C, Bashey A, Manion K, Holland HK, Morris LE, Brown S, Zhang X,
Solomon S.

-----Back To Top-----

Publications:  Highlights

Bashey ZA, Zhang X, Brown S, Jackson K, Morris LE, Holland HK, Bashey A, Solomon S, Solh MComparison of outcomes following transplantation with T-replete HLA-haploidentical donor using post-transplant cyclophosphamide to matched related and unrelated donors for patients with AML and MDS aged 60 years or older. Bone Marrow Transplant2018. June;53 (6):756-763.

Solomon S, Zhang X, Holland HK, Morris LE, Solh M, Bashey A. Superior survival of black versus white patients following post-transplant cyclophosphamide-based haploidentical transplantation for adults with hematologic malignancy.  Biology of Blood & Marrow Transplantation.  2018. June;24(6):1237-1242.

Solh M, Bashey A, Solomon S, Morris LE, Zhang X, Brown S, Holland HK.  Long term survival among patients who are disease free at 1-year post allogeneic hematopoietic cell transplantation:  a single center analysis of 389 consecutive patients.  Bone Marrow Transplant.  2018. May;53(5):576-586. 

Solomon S, Aubrey MT, Zhang X, Piluso A, Freed BM, Brown S, Jackson K, Morris LE, Holland HK, Solh M. Bashey A. Selecting the best donors for haploidentical transplant:  Impact of HLA killer cell immunoglobulin-like receptors genotyping, and other clinical variables. Biology of Blood & Marrow Transplantation. 2018.  Apr;24(4):789-798.

Spellecy R, Tarima S, Denzen E, Moore H, Abhyankar S, Dawson P, Foley A, Gersten I, Horwitz M, Idossa L, Joffe S, Kamani N, King R, Lazaryan A, Morris L, Horowitz MM, Majhail NS, Easy-to-Read Informed Consent Form for Hematopoietic Cell Transplantation Clinical Trials: Results from the Blood and Marrow Transplant Clinical Trials Network 1205 Study. Biology of Blood and Marrow Transplant, 2018 Apr 18. pii: S1083-8791(18)30195-2. doi: 10.1016/j.bbmt.2018.04.014.

Solh M. Zhang X, Connor K, Brown S, Morris LE, Holland HK, Bashey A, Solomon SR. Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation:  A single center analysis of 613 adult hematopoietic cell transplantation recipients using a modified endpoint. Biology of Blood & Marrow Transplantation. 2017. Dec;23(12):2192-2198.

Bashey A, Zhang M, Mccurdy S St. Martin A, Argall T, Ciurea S, Fasan O, Gaballa S, Hamadani M, Munshi P, Al Malki M, Nakamura R, O’Donnell P, Pereles M, Raj K, Romee R, Rowley S, Rocha V, Salit R, Solh M, Soiffer R, Fuchs E, Eapen M.  Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell replete haploidentical donor using post- transplant cyclophosphamide. Journal of Clinical Oncology. 2017 Sep10;35(26):3002-9

Webster J, Tibes R, Morris LE, et.al. Randomized Phase II Trial of Cytosine Arabinoside With and Without the CHK1 Inhibitor MK-8776 in Relapse and Refractory Acute Myeloid Leukemia.  Leukemia Research. 2017. Sept. In Press

Solh M. Zhang X, Connor K, Brown S, Morris LE, Holland HK, Bashey A, Solomon SR. Donor type and disease risk predict the success of allogeneic hematopoietic cell transplantation:  A single center analysis of 613 adult hematopoietic cell transplantation recipients using a modified endpoint. Biology of Blood & Marrow Transplantation. 2017. Aug 30.  At press.

Solomon S, Sizemore C, Zhang X, Ridgeway M, Solh M, Morris LE, Holland HK, Bashey A.  Current Graft-versus host disease free.  Relapse-free survival:  A dynamic endpoint to better define efficacy after allogenic transplant. Biology of Blood & Marrow Transplantation. 2017. Jul;23(7):1208-1214.

Gerds A, Woo a, Hu Z, Abdel Azim H, Akpek G Aljurf M, Ballen K, Beitinjaneh A, Bacher U, Cahn J, Chhabra S, Cutler C, Daly A, Deflipp Z, Gale R, Gergis U Grunwald M, Hale G, Hamilton B, Jagasia M, Kamble R, Kindwall-Keller T, Nishihori T, Olsson R, Ramanathan M, Saad A, Solh M. Ustun C, Valcarcel D, Warlick E, Wirk B, Kalaycio M, Alyea E, Popat U, Sobecks R, Saberr W. Outcomes after umbilical cord blood transplantation for myelodysplastic  Syndrome. Biology of Blood & Marrow Transplantation. 2017 June;23(6):971-79

Khoury H, Wang T, Hemmer M, Couriel D, Alousi A, Cutler C, Aljurf M, Antin  J, Ayas M, Battiwalla M, Cahn J, Cairo M, Chen Y, Gale R, Hashmi S, Hayashi R, Jagasia M, Juckett M, Kamble R, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoeman H, Schouten H, Socie G, Storek J, Verdonck L, Vij R, Wood WA Yu L, Martino R, Carabasi M, Dandoy C, Gergis U. Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz K, Wirk B, Spellman S, Arora M, Pidala J.  Improved Survival after acute graft-versus-host disease diagnosis in modern era.  Haematologica.  2017 May;102(5): 958-66.

Scott R. Solomon, Connie Sizemore, Xu Zhang, Michelle Ridgeway, Melhem Solh>, Lawrence E. Morris, H. Kent Holland, Asad Bashey, Current Graft-versus-Host Disease–Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant, Biology of Blood and Marrow Transplantationhttps://doi.org/10.1016/j.bbmt.2017.02.022

Srour S, Milton D, Bashey A, Karduss-Urueta A, Malki M, Romee R, Solomon S, Brown S, Slade M, Perez R, Rondon G, Forman S, Champlin R, Kabriaei P, Ciurea S. Haploidentical transplantation with post-transplantation cyclophosphamide for high risk acute lymphoblastic leukemia. Biology of Blood & Marrow Transplantation. 2016. Nov 14 at press.

Solomon SR, Sizemore C, Zhang X, Brown S, Holland HK, Morris LE, Solh M, Bashey A, Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia, Biology of Blood and Marrow Transplantation, October, 2016, Vol. 22, Issue 10, pages 1816–1822

Solh M, Solomon S, Morris L, Holland HK, Bashey A. Extramedullary Acute Myelogenous Leukemia. Blood. 2016. At press.

Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE, Thompson J, Horowitz MH, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder RF. Autologous hematopoietic cell transplantation for HIV-related lymphoma: Results of the BMT CTN 0803 (AMC) 071 Trial. Blood. 2016. At press.

Gorgeis J, Zhang X, Conner K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A, Solh M. T cell replete HLA-haploidentical donor transplantation (HIDT) with post-transplant cyclophosphamide (PTCY) is an effective salvage for patients relapsing after an HLA matched related (MRDT) or a matched unrelated donor transplantation (MUDT). Biology of Blood & Marrow Transplantation. 2016. At press.

Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A. Factors predicting graft-versus-host disease-free. Relapse-free survival after allogeneic hematopoietic cell transplantation: Multivariable analysis from a single center. Biology of Blood & Marrow Transplantation. 2016. Aug;22(8):1403-1409.

Solh M, Zhang X, Connor K, Brown S, Solomon SR, Morris LE, Holland HK, Bashey A. Post-relapse survival after haploidentical transplantation vs matched-related or matched unrelated hematopoietic cell transplantation. Bone Marrow Transplantation. 2016 Jul;51(7):949-54.

Oyer JL, Pandey V, Igarashi RY, Somanchi SS, Zakari A, Solh M, Lee DA, Altomare DA, Copik AJ. NK cells stimulated with PM21 particles expand and biodistribute in vivo: clinical implications for cancer treatment. Cytotherapy. 2016 May;18(5):653-63

Solh M, Shanley R, Mc Cullough J, Weisdorf D. Blood transfusions and pulmonary complications following hematopoietic cell transplantation. Transfusion. 2016 Mar;56(3):653-61

Scott R. Solomon, Haploidentical versus Matched Unrelated Donor Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia: Should Donor Type Matter Anymore? Biology of Blood and Transplantation, Volume 22, Issue 1, January 2016, Pages 125-133.

Melhem Solh, Xu Zhang, Katelin Connor, Stacey Brown, Scott R. Solomon, Lawrence E. Morris, H. Kent Holland, Asad Bashey, Factors Predicting Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center, Biology of Blood and Transplantation, Volume 22, Issue 8, August 2016, Pages 1403 - 1409.

Scott R.Solomon, Melhem Solh, Lawrence E. Morris, H.Kent Holland,and Asad Bashey, Review Article Myeloablative Conditioning with PBSC Grafts for T Cell-Replete Haploidentical Donor Transplantation Using Posttransplant Cyclophosphamide, Hindawi Publishing Corporation Advances in Hematology Volume 2016, Article ID 9736564, 7 pages http://dx.doi.org/10.1155/2016/9736564

Asad Bashey, Xu Zhang, Katelin Jackson, Stacey Brown, Michelle Ridgeway, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Scott R. Solomon, Comparison of Outcomes of Hematopoietic Cell Transplant from T-Replete Haploidentical Donors Using Post Transplant Cyclophosphamide with 10 of 10 HLA-A, -B,-C, -DRB1, and –DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis including Disease Risk Index, Biology of Blood and Transplantation, Volume 22, Issue 1, January 2016, Pages 125-133.

Scott R. Solomon, Connie A. Sizemore, Michelle Rideway, Zu Zhang, Judith Smith, Stacey Brown, H. Kent Holland, Lawrence Morris, Asad Bashey, Corticosteroid-Free Primary Treatment of Chronic Graft-Versus-Host Disease with Rituximab Results in excellent Response and Rapid Time to Immunosuppression Discontinuation, Biology of Blood and Marrow Transplantation – Accepted for publication 4-27-2015

Scott R. Solomon, Connie A. Sizemore, Melissa Sanacore, Xu Zhang, Stacey Brown, H Kent Holland, Lawrence E. Morris, Asad Bashey, TBI-based Myeloablative Haploidentical Stem Cell Transplantation is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors. Biology of Blood and Marrow Transplant, Vol. 21 Iss. 4, April 2015

Richard M. Stone, Emanuele Mazzola, Donna Neuberg, Steven L.Allen, Arnaud Pigneux, Robert K. Stuart, Meir Wetzler, David Rizzieri, Harry P.Erba, Lloyd Damon, Jun-Ho Jang, Martin S. Tallman, Krzysztof Warzocha,Tamas Masszi, Mikkael A. Sekeres, Miklos Egyed, Heinz-August Horst, Dominik Selleslag, Scott R.Solomon, Parameswaran Venugopal, Ante, S. Lundberg, and Bayard Powell. Phase III Open-Label Randomized Study of Cytarabine in Combination with Amonafide L-Malate or Daunorubicin as Induction Therapy for Patients with Secondary Acute Myeloid Leukemia. Journal of Clinical Oncology, March 2015 10.1200/JCO.2014.57.0952

Real-Life Experience of a Brief Arsenic Trioxide (ATO)-based Consolidation Chemotherapy in the Management of Acute Promyelocytic Leukemia (APL):  Favorable Outcomes with Limited Anthracycline Exposure and Shorter Consolidation Therapy, Mindy Leech, PharmD; Lawrence  Morris; Moishe  Stewart; Douglas Smith; Asad Bashey; Kent Holland; Scott Solomon; Xu Zhang; Hetty E Carraway; Keith Pratz; Steven Gore; Amer M Zeidan. Clinical Lymphoma, Myeloma & Leukemia, MS# CLML-D-14-00317R1

Solomon SR, SanacoreM, Zhang X, Brown, S, Holland K, Morris, LE, Bashey A. Calcineurin Inhibitor (DNI)-Free GVHD Prophylaxis with Post-Transplant Cyclophosphamide (CY) and Brief-Course Sirolimus Following Reduced Intensity Peripheral Blood Stem Cell Transplantation. Biology of Blood and Marrow Transplantation (2014), doi: 10,1016/j.bbmt.2014.07.020.

Bashey, A, Solomon, S. T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplantation, advance online publication, 19 May 2014; doi:10.1038/bmt.2014.62.

Solomon SR, CA Sizemore, Z  Zhang, S Brown, HK Holland, Le Morris, and A Bashey. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of alemtuzumab-containing reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial.  Bone Marrow Transplantation (2014) 49, 616-621; doi;10.1038/bmt.2014.2

Sabloff M, Sobecks RM, Ahn KW, Zhu X, De Lima M, Brown JR, Inamato Y,
Holland HK, Aijurf MD, Laughlin MJ, Kamble RT, Hsu JW, Wirk BM, Seftel M, Lewis ID, Arora M, Alyea EP, Kalaycio ME, Cortis J, Maziarz RT, Gale RP, Saber W.  Does total body irradiation conditioning improve outcoes of myeloablative human leukocyte antigen identical sibling transplantations for chronic lymphocytic leukemia.  Biology of Blood & Marrow Transplantation. 2014 Mar; 20(3) 421-424.

Freytes CO, Toro JJ, Yeh RF, Stadtmauer EA, Ratanatharathorn V, Akpek G, Sahovic E,
Tricot GJ, Shaughnessy PJ, White DJ, Rodriguez TE, Solomon SR, Yu LH, Zhao C, Patil S,
Armstrong E, Smith A, Elekes A, Kato K, Reece DE.  Safety and efficacy of targeted-dose busulfan and bortezomib as a conditioning regimen for patients with relapsed multiple myeloma undergoing a second autologous blood progenitor cell transplantation.  Biology of Blood and Marrow Transplantation. 2014, In press.

Roboz GJ, Rosenblat T, Arellano M, Gobbi M, Altman JK, Montesinos P, O’Connell C,
Solomon, SR, Pigneax A, Vey N, Hills R, Jacobsen TF, Gianella Boradori A, Foss O,
Vetrhusand S, Giles FJ.  International randomized phase III study of elacytarabine versus
investigator choice in patients with relapsed refactory acute myeloid leukemia.  Journal of
Clinical Oncology.  2014; 32(18):1919-1926.

Lancet JE, Cortes JE, Hogge DE, Tallman MS, Kovacsovics TJ, Damon LE, Komrokji R, Solomon SR, Kolitz JE, Cooper M, Yeager AM, Louie AC, Feldman EJ.  Phase 2 trial of CPX 351, a fixed 5:1 molar ratio of cytarabine/daunorubicin vs cytarabine/daunorubicin in older adults with untreated AML. Blood 2014;123(21):3239-3246.

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobaldi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J,
Lonial S, Krishnan A, Dispenzieri A, Hari P.  Salvage second hematopoietic cell transplantation cell transplantation in myeloma.  Plazma Cell Disorders Working Committee of The Blood and Marrow Transplant.  Biology of Blood & Marrow Transplantation. 2013 May; 19(5): 760-6.

Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A.  Haploididentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival:  Results of a Prospective Phase II Trial.  Biology of Blood & Marrow Transplantation.  2012 December; 18(12):  1859-1866.

Bashey A, Zhang X, Sizemore C, Manion K, Brown S, Holland HK, Morris LE, Solomon, S.  T-Cell Replete HLA-Haploidentical Hematopoietic Transplants for Hematologic Malignancies Using Post-Transplant Cyclophosphamide Result in Equivalent Outcomes to Contemporaneous Transplants From HLA-Identical and Matched Unrelated Donors.  Journal of Clinical Oncology.  2012 In Press.

Philip L. McCarthy, M.D., Kouros Owzar, Ph.D., Craig C. Hofmeister, M.D., David D. Hurd, M.D., Hani Hassoun, M.D., Paul G. Richardson, M.D., Sergio Giralt, M.D., Edward A. Stadtmauer, M.D., Daniel J. Weisdorf, M.D., Ravi Vij, M.D., Jan S. Moreb, M.D., Natalie Scott Callander, M.D., Koen Van Besien, M.D., Teresa Gentile, M.D., Ph.D., Luis Isola, M.D., Richard T. Maziarz, M.D., Don A. Gabriel, M.D., Ph.D., Asad Bashey, M.D., Ph.D., Heather Landau, M.D., Thomas Martin, M.D., Muzaffar H. Qazilbash, M.D., Denise Levitan, M.D., Brian McClune, M.D., Robert Schlossman, M.D., Vera Hars, M.S., John Postiglione, B.A., Chen Jiang, Ph.D., Elizabeth Bennett, B.H.E., Susan Barry, B.A., Linda Bressler, Pharm.D., Michael Kelly, M.A., Michele Seiler, M.S., Cara Rosenbaum, M.D., Parameswaran Hari, M.D., Marcelo C. Pasquini, M.D., Mary M. Horowitz, M.D., Thomas C. Shea, M.D., Steven M. Devine, M.D., Kenneth C. Anderson, M.D., and Charles Linker, M.D. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma N Engl J Med 2012; 366:1770-1781May 10, 2012.

Judith E. Karp, Tatiana I.Vener, Mitch Raponi, Ellen K. Ritchie, B.Douglas Smith, Steven D. Gore, Lawrence E. Morris, Eric J. Feldman, acqueline M.Greer, Sami Malek, Hetty E. Carraway, Valerie Ironside, Steven Galkin, Mark J.Levis, Michael A. McDevitt, Gail R. Roboz, Christopher D. Gocke, Carlo Derecho, John Palma, Yixin Wang, Scott H. Kaufman, John J. Wright and Elizabeth Garrett-Mayer.
Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood, 2011 October 14.

-----Back To Top-----

Michaelis LC, Saad A, Zhong X, Le-Rademacher J, Freytes CO, Marks DI, Lazarus HM, Bird JM, Holmberg L, Kamble RT, Kumar S, Lill M, Meehan KR, Saber W, Schriber J, Tay J, Vogl DT, Wirk B, Savani BN, Gale RP, Vesole DH, Schiller GJ, Abidi M, Anderson KC, Nishihori T, Kalaycio ME, Vose JM, Moreb JS, Drobyski W, Munker R, Roy V, Ghobaldi A, Holland HK, Nath R, To LB, Maiolino A, Kassim AA, Giralt SA, Landau H, Schouten HC, Maziarz RT, Michael J, Kindwall-Keller T, Stiff PJ, Gibson J,
Lonial S, Krishnan A, Dispenzieri A, Hari P.  Salvage second hematopoietic cell transplantation cell transplantation in myeloma.  Plazma Cell Disorders Working Committee of The Blood and Marrow Transplant.  Biology of Blood & Marrow Transplantation. 2013 May; 19(5): 760-6.

Solomon S, Sizemore C, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A.  Haploididentical Transplantation Using T-Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival:  Results of a Prospective Phase II Trial.  Biology of Blood & Marrow Transplantation.  2012 December; 18(12):  1859-1866.

Bashey A, Zhang X, Sizemore C, Manion K, Brown S, Holland HK, Morris LE, Solomon, S.  T-Cell Replete HLA-Haploidentical Hematopoietic Transplants for Hematologic Malignancies Using Post-Transplant Cyclophosphamide Result in Equivalent Outcomes to Contemporaneous Transplants From HLA-Identical and Matched Unrelated Donors.  Journal of Clinical Oncology.  2012 In Press.

Philip L. McCarthy, M.D., Kouros Owzar, Ph.D., Craig C. Hofmeister, M.D., David D. Hurd, M.D., Hani Hassoun, M.D., Paul G. Richardson, M.D., Sergio Giralt, M.D., Edward A. Stadtmauer, M.D., Daniel J. Weisdorf, M.D., Ravi Vij, M.D., Jan S. Moreb, M.D., Natalie Scott Callander, M.D., Koen Van Besien, M.D., Teresa Gentile, M.D., Ph.D., Luis Isola, M.D., Richard T. Maziarz, M.D., Don A. Gabriel, M.D., Ph.D., Asad Bashey, M.D., Ph.D., Heather Landau, M.D., Thomas Martin, M.D., Muzaffar H. Qazilbash, M.D., Denise Levitan, M.D., Brian McClune, M.D., Robert Schlossman, M.D., Vera Hars, M.S., John Postiglione, B.A., Chen Jiang, Ph.D., Elizabeth Bennett, B.H.E., Susan Barry, B.A., Linda Bressler, Pharm.D., Michael Kelly, M.A., Michele Seiler, M.S., Cara Rosenbaum, M.D., Parameswaran Hari, M.D., Marcelo C. Pasquini, M.D., Mary M. Horowitz, M.D., Thomas C. Shea, M.D., Steven M. Devine, M.D., Kenneth C. Anderson, M.D., and Charles Linker, M.D. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma N Engl J Med 2012; 366:1770-1781May 10, 2012.

Judith E. Karp, Tatiana I.Vener, Mitch Raponi, Ellen K. Ritchie, B.Douglas Smith, Steven D. Gore, Lawrence E. Morris, Eric J. Feldman, acqueline M.Greer, Sami Malek, Hetty E. Carraway, Valerie Ironside, Steven Galkin, Mark J.Levis, Michael A. McDevitt, Gail R. Roboz, Christopher D. Gocke, Carlo Derecho, John Palma, Yixin Wang, Scott H. Kaufman, John J. Wright and Elizabeth Garrett-Mayer. Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood, 2011 October 14.

Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Soiffer R, Mitrovich RC, Lowy I, Ball ED.  CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not increased levels of T regulatory cells.  Biology of Blood & Marrow Transplantation. 2010 Aug 13. Kasamon Y, Luznik L, Leffell M, Kowalski J, Tsai H, Bolanos-Meade J, Morris LE, Crilley P, O’donnell P, Rossiter N, Huff C, Brodsky R.  Nonmyeloablative HLA-
haploidentical BMT with high dose posttransplantation cyclophosphamide:  analysis of outcomes in relation to HLA disparity.  Biology of Blood and Marrow Transplantation.2010 April;16(4): 482-9.

Solomon SR, Matthews RH, Barreras AM, Bashey A, Manion KL, McNatt K, Speckhart D. Connaghan DG, Morris LE, Holland HK.  Outpatient myeloablative  allo-SCT:  a comprehensive approach yields decrease hospital utilization and  low TRM.  Bone Marrow Transplantation.  2010 March;45(3): 468-75.

Gore S, Gojo I, Sekeres M, Morris LE, et al.  A Single Cycle of arsenic trioxide- based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.  Journal of Clinical Oncology 2010 Feb 20; 28(6): 1047-53.

Karp J, Flatten K, Feldman E, Greer J, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith DB, IronsideV, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore S, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous   leukemia: A preclinical and phase I trial of the farnesyltransferase inhibitor tripifarnib (R115777, Zarnestra) combined with etoposide.  Blood. 2009 May 14;113(20): 4841-52.

Kebriaei P, Isola L, Bahceci E, Holland HK, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Uberti J.  306:  Successful phase II trial using Mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft-vs-host disease (aGVHD).  Biology of Blood and Marrow Transplantation.  2007 Feb;3(2): 111.

Judith E. Karp, Tatiana I.Vener, Mitch Raponi, Ellen K. Ritchie, B.Douglas Smith, Steven D. Gore, Lawrence E. Morris, Eric J. Feldman, acqueline M.Greer, Sami Malek, Hetty E. Carraway, Valerie Ironside, Steven Galkin, Mark J.Levis, Michael A. McDevitt, Gail R. Roboz, Christopher D. Gocke, Carlo Derecho, John Palma, Yixin Wang, Scott H. Kaufman, John J. Wright and Elizabeth Garrett-Mayer.

Multi-institutional Phase II clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia. Blood, 2011 October 14.

Bashey A, Owzar K, Johnson JL, Edwards PS, Kelly M, Baxter-Lowe LA, Devine S, Farag S, Hurd D, Ball E, McCarthy P, Lister J, Shea TC, Linker C.  Reduced – Intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation:  A multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).  Biology of Blood & Marrow Transplantation. 2011 Apr;17(4) 558-65.

Shea T, Johnson J, Westervelt P, Farag S, McCarty J, Bashey A, Isola L, Baxter-Lowe LA, Kelly M, Owzar K, Linker C; For the Cancer leukemia Group B.   Reduced-intensity Allogeneic transplantation provides high event-free and overall survival in patients with advanced indolent B cell malignancies:  CALGB 109901. Biology of Blood & Marrow Transplantation.  2011 Feb 3.

Reese DE, Vesole DH, Shrestha S, Zhang MJ, Perez WS, Dispenzieri A, Milone GA, Abidi M, Atkins H, Bashey A, Bredeson CN, Boza WB, Freytes CO, Gale RP, Gajewski JL, Gibson J, Hale GA, Kumar S, Kyle RA, Lazarus HM, McCarthy PL, Pavlovsky S, Roy V, Weisdorf DJ, Wiernik PH, Hari PN.  Outcome of patients with IgD and IgM Multiple Myeloma undergoing Autologous hematopoietic stem cell transplantation:  A retrospective CIBMTR Study.  Clinical Lymphoma Myeloma Leukemia. 2010 Dec1;10(6): 458-63.

Chu R, Bazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, Chiang KY, Frangoul H, Gale RP, Gee A, George B, Goldman FD, Gross TG, Gupta V, Hale GA, Isola L, Ispizua AU, Lazarus H, Marsh J, Russell J, Sabloff M, Waller EK, Eapen M.  Comparison of outcomes after transplantation of G-CSF – stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. Biology of Blood & Marrow Transplantation. 2010 October 27.

Zhou J, Bashey A, Zhong R, Corringham S, Messer K, Pu M, Ma W, Soiffer R, Mitrovich RC, Lowy I, Ball ED.  CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not increased levels of T regulatory cells.  Biology of Blood & Marrow Transplantation. 2010 Aug 13.

Kasamon Y, Luznik L, Leffell M, Kowalski J, Tsai H, Bolanos-Meade J, Morris LE, Crilley P, O’donnell P, Rossiter N, Huff C, Brodsky R.  Nonmyeloablative HLA- haploidentical BMT with high dose posttransplantation cyclophosphamide:  analysis of outcomes in relation to HLA disparity.  Biology of Blood and Marrow Transplantation.2010 April;16(4): 482-9.

Ballen K, Shrestha S, Sobocinski K, Zhang M, Bashey A, Bolwell B, Cervantes F, Devine S, Gale R, Gupta V, Hahn T, Hogan W, Kroger N, Litzow M, Marks D, Maziarz R, McCarthy P, Schiller G, Schouten H, Wiernik P, Horowitz M, Giralt S, Arora M.  Outcome of  transplantation for myelofibrosis.  Biology of Blood & Marrow Transplantation. 2010 March; 16(3): 358-67.

Hari P, Majhail N, Zhang M, Hassebroek A, Siddiqui F, Ballen K. Bashey A, Bird J, Freytes C, Gibson J, Hale G, Holmberg L, Kamble R, Kyle R, Lazarus P, LeMaistre C, Loberiza F, Maiolino A, McCarthy P, Milone G, Omondi N, Reece D, Seftel M, Trigg M, Vesole D, Weiss B, Wiernik P, Lee S, Rizzo J, Mehta P.  Race and outcomes of autologous hematopoietic cell transplantation for multiple myeloma.  Biology of Blood & Marrow Transplantation. 2010 March;16(3): 395-402.

Solomon SR, Matthews RH, Barreras AM, Bashey A, Manion KL, McNatt K, Speckhart D. Connaghan DG, Morris LE, Holland HK.  Outpatient myeloablative allo-SCT:  a comprehensive approach yields decrease hospital utilization and low TRM.  Bone Marrow Transplantation.  2010 March;45(3): 468-75.

Gore S, Gojo I, Sekeres M, Morris LE, et al.  A Single Cycle of arsenic trioxide- based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia.  Journal of Clinical Oncology 2010 Feb 20; 28(6): 1047-53.

Schiller GL, O'Brien SM, Pigneux A, DeAngelo DJ, Vey N, Kell J, Solomon S, Stuart RK, Karsten V, Cahill AL, Albitar MX, Giles FJ.  Single-Agent Laromustine, A Novel Alkylating Agent, Has Significant Activity in Older Patients With Previously Untreated Poor-Risk Acute Myeloid Leukemia.  J Clin Onc 2010; 28(5):815-821.

Jung A, Holman P, Castro J, Carrier E, Bashey A, Lane T, Nelson C, Pu M, Messer K, Corringham S, Ball E.  Autologous hematopoietic stem cell transplantation as an intensive consolidation therapy for adult patients in remission from acute myelogenous leukemia. Biology of Blood & Marrow Transplantation.  2009 Oct;15(10): 1306-13.

Hari P, Zhang M, Roy V, Perez W, Bashey A, To LB, Elfenbein G, Freytes C, Gale R, Gibson J, Kyle R, Lazarus H, McCarthy P, Milone G, Pavlovsky S, Reece D, Schiller G, Vela-Ojeda J, Weisdorf D, Vesole D.  Is the international staging system superior to the Durie-Salmon staging System?  A comparison in multiple myeloma patients undergoing autologous transplant. Leukemia. 2009 August;23(8): 1528-34.

Karp J, Flatten K, Feldman E, Greer J, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith DB, IronsideV, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore S, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann S.H. Active oral regimen for elderly adults with newly diagnosed acute myelogenous   leukemia: A preclinical and phase I trial of the farnesyltransferase inhibitor tripifarnib (R115777, Zarnestra) combined with etoposide.  Blood. 2009 May 14;113(20): 4841-52.

Bashey A, Medina B, Corringham S, Pasek M, Carrier E, Vrooman L, Lowy I, Solomon SR, Morris LE, Holland HK, Mason JR, Alyea EP, Soiffer RJ, Ball ED.  CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation.  Blood.  2009 Feb 12; 113(7): 1581-8.

Kumar S, Perez WS, Zhang MJ, Ballen K, Bashey A, To LB, Bredeson CN, Cairo MS, Elfenbein GJ, Freytes CO, Gale RP, Gibson J, Kyle RA, Lacy MQ, Lazarus HM, McCarthy PL, Milone GA, Moreb JS, Pavlovsky S, Reese DE, Vesole DH, Wiernik PH, Hari P.  Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biology of Blood & Marrow Transplantation. 2008 Oct;14;(10): 1134-40.

Bashey A, Perez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR, To LB, Fonseca R, Freytes CO, Gale RP, Gibson J, Giralt SA, Kyle RA, Lazarus HM, Maharaj D, McCarthy PL, Milone GA, Nimer S, Pavlovsky S, Reece DE, Schiller G, Vesole DH, Hari P, Plasma Cell Disorders Working Committee. Comparison of Twin and autologous transplants for multiple myeloma.  Biology of Blood & Marrow
Transplantation. 2008 Oct; 14(10): 1118-24.

Smith SM, Van Besien K, Carreras J, Bashey A, Cairo MS, Freytes CO, Gale RP, Hale GA, Hayes-Lattin B, Holmberg LA, Keating A, Maziarz RT, McCarthy PL, Navarro WH, Paviovsky S, Schouten HC, Seftel M, Wiernik PH, Vose JM, Lazarus HM, Hari P. Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biology of Blood & Marrow Transplantation. 2008 Aug;14(8):904-12

Karp JE, Smith BD, Gojo I, Lancet JE, Greer J, Klein M, Morris LE, Levis MJ, Gore SD, Wright JJ, Garrett-Mayer E. Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor risk features.  Clinical Cancer Research. 2008 May; 14(10):
3077-82.

Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D.  Allogeneic. Hematopoietic cell transplantation for metastatic breast cancer.  Bone Marrow Transplant.  2008, Mar;41(6): 537-45.

Raponi M, Lancet J, Hongtao F, Dossey L, Lee G, Gojo I, Feldman E, Gotlib J, Morris LE, Greenberg P, Wright J, Harousseau J, Lowenberg B, Stone R, De Porre P, Wang Y, Karp J.  A two-gene classifier for predicting response  to the farnesyltransferase Ihibitor tipifarnib in acute myeloid leukemia. Blood. 2008 Mar 1; 111(5): 2589-96.

Schlenk RF, Pasquini MC, Perez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Buchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Dohner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A; CIBMTR Acute Leukemia Working Committee.  HLA-Identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission:  Collaborative study between the German AML Intergroup and CIBMTR.  Biology of Blood & Marrow Transplantation.  2008 Feb; 14(2):187-96.

Karp JE, Giles FJ, Gojo I, Morris LE, Greer J, Johnson B, Thein M, Low J. A phase 1 study of the novel ribonucleotide reductase inhibitor 3- aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders. Leukemia Research. January 2008; 32(1): 71-7.

Bashey A, Donohue M, Lin L, Medina B, Corringham S, Ihasz A, Carrier E, Castro J, Holman P, Ronghui X, Law P, Ball E, Lane T.  Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-simulating factor and granulocyte-
colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.  Transfusion, 2007 Nov; 47(11): 2153-60

Mielke S, Rezvani K, Savani B, et al.  Reconstitution of foxp3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease (GvHD). Blood 2007 Sep; 110:1689-97.

Baek W, Bashey A, Sheean G.  Complete remission induced by rituximab in refractory, seronegative, muscle specific, kinase-positive myasthenia gravis.  J Neurol Neurosurg Psychiatry, 2007, July;78(7):  771.

Matthews RH, Emami M, Connaghan DG, Holland HK, Morris LE.  Home administration of high-dose oral busulfan in patients undergoing hematopoietic stem cell transplantation.  Bone Marrow Transplantation. 2007 Apr;39(7): 397-400.

Lancet J, Gojo I, Gotlib J, Feldman E, Greer J, Liesveld J, Bruzek L, Morris L, et.al: A Phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.  Blood. 2007 Feb15; 109(4):1387-1394.

Kebriaei P, Isola L, Bahceci E, Holland HK, Rowley S, McGuirk J, Devetten M, Jansen J, Herzig R, Schuster M, Uberti J.  306:  Successful phase II trial using Mesenchymal stem cells (MSC) in combination with steroid therapy for the primary treatment of acute graft-vs-host disease (aGVHD).  Biology of Blood and Marrow Transplantation.  2007 Feb;3(2): 111.

Anagnostopoulos A, Hari P, Perez W, Ballen K, Bashey A, Bredeson C, Freytes C, Gale R, Gertz M, Gibson J, Goldschmidt H, Lasarus H, McCarthy P, Reece D, Vesole D, Giralt S.  Autologous or allogeneic stem cell transplantation in patients with Waldenstrom’s macroglobulinemia.  Biology of Blood & Marrow Transplantation, 2006, Aug;12(8):  845-54.

Melenhorst JJ, Solomon SR, Shenoy A, et al.  Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunotherapy. 2006 Jul-Aug;29(4):436-43

Bashey A, Liu L, Ihasz A, Medina B, Corringham S, Keese K, Carrier E, Castro JE, Holman P, Lane TA,
Hassidim K, and Ball ED. Non-anthracycline based remission induction therapy for newly diagnosed patients with acute myeloid leukemia aged sixty or older. Leukemia Res., 2006, April;30(4): 503-6.

Tallman M, Perez W, Lazarus H, Gale R, Maziarz R, Rowe J, Marks D, Cahn J, Bashey A, Bishop M, Christiansen N, Frankel S, Garcia J, Llhan O, Laughlin M, Liesveld J, Linker C, Litzow M, Luger S, McCarthy P, Milone G, Pavlovsky S, Phillips G, Russell J, Saez R, Schiller G, Sierra J, Weiner R, Zander A, Zhang M, Keating A, Weisdorf D, Horowitz M.  Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission.  Biology of Blood & Marrow Transplantation, 2006, Feb;12(2):  204-16.

Montero A, Savani BN, Kurlander R, Read EJ, Leitman SF, Childs R, Solomon SR, Barrett AJ.
Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. British Journal of  Hematology. 2005 Sep;130(5):733-9.

Gore SD, Smith DB, Gojo I, Morris LE, et al:  Durable molecular remission with a single cycle of timed sequential consolidation chemotherapy in acute   promyelocytic leukemia.  American Journal of Hematology.  2005 June; 79(2): 119 -127.

Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK,  Shpall EJ, McCarthy P, et. al.  Cotransplantation of HLA-Identical Sibling Culture-Expanded Mesenchymal Stem Cells and Hematopoietic Stem Cells in Hematologic Malignancy Patients.  Biology of Blood and Marrow Transplantation: 2005 May; 11(5): 389-98.

Solomon SR, Savani B, Montero A, et al.  Improved Outcomes for Peripheral Blood Stem Cell Transplantation for Advanced Primary Myelodysplastic Syndrome.  Biology of Blood Marrow Transplant 2005; 11:619-26

Solomon SR, Mielke S, Savani BN, et al.  Selective depletion of alloreactive donor lymphocytes- a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood. 2005; 106(3):1123-9.

Mielke S, Solomon SR, and Barrett AJ.  Selective Depletion Strategies in Allogeneic Stem Cell Transplantation.  Cytotherapy 2005; 7(2):109-15.

Savani BN, Montero A, Wu C, Nlonda N, Read E, Dunbar C, Childs R, Solomon S, and Barrett AJ.  Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation. Biology of Blood Marrow Transplant 2005; 11:223-230.

Karp J, Gojo I, Pili R, Morris LE, et al.  Targeting vascular endothelial growth factor (VEGF) for relapsed and refractory adult acute myelogenous leukemias: therapy with  sequential 1-beta-d- arabinofuranosylcytosine, mitoxantrone, and bevacizumab. Clinical Cancer Research.  2004 June1;
10(11): 3577-85.

Jacobsohn DA, Anders V, McMillan S, Morris LE, et al: Infliximab for the treatment of acute GVHD:  A review and case series. American Journal of Hematology. 2003 Oct; 74(2): 119-24.

Reece DE, Foon KA, Bhattarcharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DA, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL.  Use of the anti-idiotype Breast Cancer Vaccine 11D10 in Conjuction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer, Clinical Breast Cancer, 2003 Feb;3 Suppl 4: S152-7.

Reece DE, Foon, KA, Battacharya-Chatterjee M, Adkins D, Broun ER, Connaghan DG, Dipersio JF, Holland HK, Howard DS, Hale GA, Klingemann HG, Munn RK, Raptis A, Phillips GL.  Interim Analysis of the use of the Anti-Idiotype Breast Cancer Vaccine 11D10 (TriAb) in conjunction with Autologous Stem Cell Transplantation in Patients with Metastatic Breast Cancer, Clinical Breast Cancer, 2001 Apr;2(1): 52-8.

Owen P, Connaghan DG, Holland HK, Steis RG.  Bone Marrow Transplantation: Cancer therapy comes of age.  Journal of Medical Association of Georgia, 1998 Apr;87(2): 145-6, 148.

Bomberger C, Singh–Jairam M, Rodney G, Guerriero A,Yeager AM, Fleming WH, Holland HK, Waller EK.  Lymphoid Reconstitution Following Autologous PBSC Transplantation with FACS sorted CD34+ Hematopoietic Progenitors. Blood, 1998 Apr1;91(7): 2588- 600.